A cellular assay for measuring the modulation of glucose production in H4IIE cells

Assay and Drug Development Technologies

Volumn 4, Issue 5, 2006, Pages 525-533

  de Raemy Schenk, Anne Marie ^a   Troublé, Solenne ^a   Gaillard, Pascale ^a   Page, Patrick ^a   Gotteland, Jean Pierre ^a   Scheer, Alexander ^a   Lang, Paul ^a   Yeow, Karen ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DIMETHYL SULFOXIDE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INSULIN; METFORMIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GLUCONEOGENESIS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; RAT;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; INSULIN; LIVER NEOPLASMS, EXPERIMENTAL; METABOLIC CLEARANCE RATE; RATS;

EID: 33845874108     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.4.525     Document Type: Article

References (51)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
2. Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
3. Link JT: Pharmacological regulation of hepatic glucose production. Curr Opin Investig Drugs 2003;4:421-429.
4. Eldar-Finkelman H: Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002;8:126-132.
5. Jope RS, Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
6. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-527.
7. Lochhead PA, Coghlan M, Rice SQ, Sutherland C: Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes 2001;50:937-946.
8. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR: Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000;49:263-271.
9. Henry RR, Ciaraldi TP, Brams-Carter L, Mudaliar S, Park KS, Nikoulina SE: Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. Biochemical and molecular mechanisms. J Clin Invest 1996;98:1231-1236.
10. Eldar-Finkelman H, Krebs EG: Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 1997;94:9660-9664.
11. Dokken BB, Sloniger JA, Henriksen EJ: Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2005;288:E1188-E1194.
12. MacAulay K, Hajduch E, Blair AS, Coghlan MP, Smith SA, Hundal HS: Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase. Eur J Biochem 2003;270:3829-3838.
13. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
14. Roach PJ: Glycogen and its metabolism. Curr Mol Med 2002;2:101-120.
15. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 2003;305:974-980.
16. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, et al.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003;52: 588-595.
17. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487.
18. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR: Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 2002;51:2190-2198.
19. Yeow K, Novo-Perez L, Gaillard P, Page P, Gotteland J-P, Scheer A, et al.: A cellular assay for measuring the inhibition of glycogen synthase kinase-3 via the accumulation of β-catenin in Chinese hamster ovary clone K1 cells. Assay Drug Dev Technol 2006;4:451-460.
20. Benedict WF, Gielen JE, Owens IS, Niwa A, Bebert DW: Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. IV. Stimulation of the enzyme activity in established cell lines derived from rat or mouse hepatoma and from normal rat liver. Biochem Pharmacol 1973;22: 2766-2769.
21. Pitot HC, Peraino C, Morse PA Jr, Potter VR: Hepatomas in tissue culture compared with adapting liver in vivo. Natl Cancer Inst Monogr 1964;13:229-245.
22. Carboni S, Antonsson B, Gaillard P, Gotteland JP, Gillon JY, Vitte PA: Control of death receptor and mitochondrial-dependent apoptosis by c-Jun N-terminal kinase in hippocampal CA1 neurones following global transient ischaemia. J Neurochem 2005;92:1054-1060.
23. 2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 2004;310:25-32.
24. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, et al.: Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 2005;48:4596-4607.
25. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
26. Valera A, Bosch F: Glucokinase expression in rat hepatoma cells induces glucose uptake and is rate limiting in glucose utilization. Eur J Biochem 1994;222:533-539.
27. Duong DT, Waltner-Law ME, Sears R, Sealy L, Granner DK: Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem 2002;277:32234-32242.
28. Gao Y, Walder K, Sunderland T, Kantham L, Feng HC, Quick M, et al.: Elevation in Tanis expression alters glucose metabolism and insulin sensitivity in H4IIE cells. Diabetes 2003;52:929-934.
29. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al.: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131-138.
30. Wellington K: Rosiglitazone/metformin. Drugs 2005;65: 1581-1592.
31. Morioka K, Nakatani K, Matsumoto K, Urakawa H, Kitagawa N, Katsuki A, et al.: Metformin-induced suppression of glucose-6-phosphatase expression is independent of insulin signaling in rat hepatoma cells. Int J Mol Med 2005; 15:449-452.
32. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al.: Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-1132.
33. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, et al.: Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004;279:45803-45809.
34. Ceppi ED, Smith FS, Titheradge MA: Effect of multiple cytokines plus bacterial endotoxin on glucose and nitric oxide production by cultured hepatocytes. Biochem J 1996; 317:503-507.
35. Gustafson LA, Neeft M, Reijngoud DJ, Kuipers F, Sauerwein HP, Romijn JA, et al.: Fatty acid and amino acid modulation of glucose cycling in isolated rat hepatocytes. Biochem J 2001;358:665-671.
36. Bergmeyer HU: Methods of Enzymatic Analysis, 2nd ed. Verlag Chemie, Weinheim, Germany; Academic Press, Inc., London, 1974.
37. van Dijk TH, van der Sluijs FH, Wiegman CH, Baller JF, Gustafson LA, Burger HJ, et al.: Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem 2001;276:25727-25735.
38. Sanchez-Gutierrez JC, Sanchez-Arias JA, Samper B, Feliu JE: Modulation of epinephrine-stimulated gluconeogenesis by insulin in hepatocytes isolated from genetically obese (fa/fa) Zucker rats. Endocrinology 1997;138:2443-2448.
39. Yu B, Pugazhenthi S, Khandelwal RL: Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem Pharmacol 1994;48:949-954.
40. Snehalatha C, Ramachandran A, Satyavani K, Vijay V, Haffner SM: Specific insulin and proinsulin concentrations in nondiabetic South Indians. Metabolism 1999;47:230-233.
41. Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M: The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 1997;46:1990-1995.
42. Crowley WR, Ramoz G, Keefe KA, Torto R, Kalra SP, Hanson GR: Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats. Neuroscience 2005;132:167-173.
43. Jia D, Taguchi M, Otsuki M: Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats. Metabolism 2005;54:619-627.
44. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554.
45. Orena SJ, Torchia AJ, Garofalo RS: Inhibition of glycogen-synthase kinase 3 stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 2000;275:15765-15772.
46. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, et al.: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006;5:1007-1013.
47. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, et al.: A selective small molecule IkappaB kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 2006;317:989-1001.
48. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al.: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945.
49. Lee YH, Giraud J, Davis RJ, White MF: c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003;278:2896-2902.
50. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al.: A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336.
51. Parandoosh Z: Cell-based assays. J Biomol Screen 1997;2: 201-202.